IPHA

MARSEILLE, France, October 20, 2026--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announces that the Company will hold a conference call on Thursday, November 5, 2026, at 2 p.m. CET / 8 a.m. ET, to provide a business and financial update for the third quarter of 2026. Participants during the call will be: - Jonathan Dickinson, Chief Executive Officer - Markus Jensen, Vice President, Chief Medical Officer - Yannis Morel, Executive Vice President, Chief Operating Officer - Stéphanie Cornen, Vice President, Investor Relations and Communications - Frédéric Lombard, Senior Vice President, Chief Financial Officer Event details - Date and time: November 5, 2026 at 2:00 p.m. CET / 8:00 a.m. ET - Webcast link: Click here - Conference call link: Click here This information is also available on the Investors section of the Innate Pharma website, www.innate-pharma.com. A replay of the webcast will be available on the Company website for 90 days following the event. About Innate Pharma Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise in antibody engineering and innovative target identification, Innate Pharma is developing innovative and differentiated next-generation antibody therapeutics. Innate Pharma is advancing a portfolio of differentiated potential first- and/or best-in-class assets, focused on areas of high unmet medical need. Its proprietary pipeline is centered on antibody-drug conjugates (ADCs), led by IPH4502, a differentiated Nectin-4 ADC in clinical development for solid tumors, and supported by a preclinical portfolio of next-generation ADC candidates. In parallel, Innate is advancing two partnered late-stage assets: lacutamab, developed with Sobi for cutaneous T-cell lymphomas, and monalizumab, developed with AstraZeneca for non-small cell lung cancer (NSCLC). Innate Pharma has established collaborations with leading biopharmaceutical companies, including Sobi, Sanofi and AstraZeneca, as well as renowned academic and research institutions, to advance innovation in immuno-oncology. Headquartered in Marseille, France, Innate Pharma is listed on Euronext Paris and Nasdaq in the US. Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X. Information about Innate Pharma shares ISIN code Ticker code LEI | FR0010331421Euronext: IPH Nasdaq: IPHA9695002Y8420ZB8HJE29 Disclaimer on forward-looking information and risk factors For a discussion of risks and uncertainties, please refer to the Risk Factors ("Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority ("AMF"), which is available on the AMF website (www.amf-france.org) or on Innate Pharma's website (http://www.innate-pharma.com), and public filings and reports filed with the U.S. Securities and Exchange Commission ("SEC"), including the Company's Annual Report on Form 20-F for the year ended December 31, 2025, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company's website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country. View source version on businesswire.com: https://www.businesswire.com/news/home/20261019551853/en/ Contacts Stéphanie Cornen [email protected] Investor Relations [email protected] Media [email protected]

Image source: The Motley Fool. Thursday, Sept. 17, 2026, at 8 a.m. ET Chief Executive Officer-Jonathan E. Dickinson Chief Medical Officer-Sonia Quaratino Chief Operating Officer-Yannis Morel Chief Financial Officer-Frederic Lombard Vice President of Investor Relations, Communication, and Commercial-Stephanie Cornen Operator: Hello, everyone. Thank you for joining us. And welcome to the Innate Pharma First Half 2026 Business Update and Financial Results. After today's prepared remarks, we will host a question-and-answer session. If you would like to ask a question, please press star 1 to raise your hand. To withdraw your question, press star 1 again. I will now hand the conference over to Stephanie Cornen, Vice President of Investor Relations, Communication, and Commercial. Stephanie, please go ahead. Stephanie Cornen: Good morning, and good afternoon, everyone. Thank you for joining us for Innate Pharma's first half 2026 business updates and financial results conference call. The press release and today's presentation are both available on the IR section of our website. Before we begin, I would like to remind everyone that today's presentation includes forward-looking statements based on current expectations. These statements involve risks and uncertainties that could cause actual results to differ materially. Briefly covering today's agenda, our CEO, Jonathan E. Dickinson, will begin with a strategic overview and outlook. Sonia Quaratino, our chief medical officer, and Yannis Morel, our chief operating officer, will then take us through updates on IPH4.5 thousand monalizumab, and our preclinical ADC pipeline. Frederic Lombard, our chief financial officer will then review our financial results. Jonathan will return for our upcoming catalysts and closing remarks. Before we open the call for Q&A. With that, I will now hand it over to Jonathan. Jonathan E. Dickinson: Thank you, Stephanie. Good morning to those joining from the US. And good afternoon to our European participants. Turning to Slide 5, the first half of 2026 together with development since the end of the period has been marked by important progress across our focus portfolio. Starting with lacutamab, in August, we announced our strategic partnership with Sobe to advance the program in T cell lymphoma. As announced yesterday, that partnership is now effective following the closing of the deal. And the TELLOMAK-3 Phase 3 has been initiated. We are targeting the first patient in the study in Q1 2027 as we work toward a filing for accelerated approval in Sezary Syndrome in 2027. For IPH4.5 thousand as announced in July, we completed Phase 1 dose escalation and cohort enrichment enrollment, and have seen preliminary antitumor activity including objective responses in post EV urothelial cancer. As well as in non small cell lung cancer, and head and neck cancer. With a favorable safety profile observed to date. We will share initial Phase 1 dose escalation data at the URTC NCI AACR meeting on November 18, 2026, in Barcelona. Turning to monalizumab, enrollment in the PACIFIC-9 Phase 3 study has been completed. And we continue to expect the Phase 3 readout in the second half of 2026. Financially, our position has been strengthened by the 75 million Sobe upfront payment associated with the closing of the deal. And the 30 million equity financing. Together, these are expected to extend our projected cash runway through the end of the first quarter of 2028. Taken together, we believe these developments position NAEP for several important catalysts in the second half of 2026. Let me start with lacutamab, Lacutamab is our anti-KIR3DL2 antibody being developed in cutaneous T cell lymphoma or CTCL. Turning to slide 7, As I mentioned, in August, we announced a strategic partnership with Sobe to license lacutamab in T cell lymphoma. The transaction has now closed. TELLOMAK-3, our confirmatory Phase 3 study in CTCL has been initiated. With the first patient expected in the first quarter of 2027. Innate will conduct the Phase 3 study and we will file for accelerated approval in Sezary Syndrome based on the existing Phase 2 TELLOMAK data. Upon the potential accelerated approval, Sobe will receive exclusive global rights to commercialize lacutamab. Following positive Phase 3 results, Sobe will be eligible to obtain full global development rights. Under the terms of the agreement, the transaction includes a 75 million upfront payment up to 40 million in near term milestones connected to Sezary Syndrome. And up to an additional $465 million related to Sobe's option to obtain full development rights and future re regulatory and commercial milestones. Agreement also includes tiered double digit royalties on future net sales. I will now hand it over to Sonia to review the regulatory and development path forward. Sonia? Sonia Quaratino: Thank you, Jonathan. Lacutamab is now progressing toward Phase 3 TELLOMAK-3 initiation and planned accelerated approval filing. So from a regulatory and development perspective, the path forward is well defined. We have FDA clearance to proceed with TELLOMAK-3. Which now has been initiated with the first patient expected in the first quarter 2027. The study includes a confirmatory cohort in Sezary Syndrome and a registrational cohort in mycosis fungoides. The existing Phase 2 TELLOMAK data are intended to support an accelerated approval filing in Sezary Syndrome once TELLOMAK-3 is underway. With a filing currently planned for the second half of 2027. As a reminder, lacutamab has received breakthrough therapy designation from the FDA for relapsed or refractory Sezary Syndrome as well as fast track designation from the FDA, PRIME designation from the EMA, and an orphan drug status in both United States and Europe. So with the regulatory pathway is established and the Sobe partnership now effective, our focus is on advancing TELLOMAK-3 toward first patient enrollment in the first quarter of 2027. Turning to the next slide, please. I now move to IPH4.5 thousand. Our differentiated Nectin-4 exatecan ADC. Which is in Phase 1 development for advanced solid tumors. IPH4.5 thousand was designed to address some of the key limitations of the first generation of Nectin-4 ADCs. The molecule combines an exatecan topoisomerase-I payload with our proprietary stable linker and a high-affinity Nectin-4 antibody that binds non overlapping epitope compared with enfortumab vedotin. We believe these features provide an important point of differentiation as the Nectin-4 ADC landscape continues to evolve. Importantly, we are now beginning to see that profile translate clinically. We have observed preliminary antitumor activity with objective responses in heavily pretreated patients, including patients with urothelial cancer following prior enfortumab vedotin treatment as well as in non small cell lung cancer, head and neck cancer. The safety profile observed to date has been favorable with limited hematological. Toxicity. We completed dose escalation in July, and a broadly tracking in line with our expectations across expansion cohorts with approximately 15 patients enrolled in both post TB urothelial cancer, head and neck cancer, and somewhat lower enrollment in the non-small cell lung cancer cohort. Data cleaning is ongoing, and we look forward to presenting the initial Phase 1 dose escalation dataset at the EORTC NCI AACR Symposium on November 18, 2026. Next slide, please. An area of particular interest for IPH4.5 thousand is urothelial cancer. following prior EV treatment. While EV plus pembrolizumab has significantly changed the treatment landscape, Most patients progress within 2 years. And there remains no established second line standard of treatment after progression on this regimen. Against that backdrop, the preliminary activity we have observed with IPH4.5 thousand in heavily pretreated post-EV patients including objective responses, is encouraging. These remain early Phase 1 observations, and the upcoming dataset will help us determine how to best advance the program. Slide 12, please. I now move forward to monalizumab. Which is our NKG2A antibody being codeveloped with AstraZeneca in non small cell lung cancer. PACIFIC-9 is a randomized Phase 3 trial with unresectable Stage III non small cell lung cancer. Patients who have not progressed following a definitive platinum based concurrent chemoradiotherapy. Study enrolled 1.05 thousand patients in a comparison to nivolumab plus oliclumab, duvalumab plus monalizumab, and duvalumab plus placebo with progression-free survival as the primary endpoint. The program is supported by 3 earlier Phase 2 studies in non small cell lung cancer, including COAST, NeoCOAST, and NeoCOAST-2. With enrollment complete, Phase 3 data remain expected in the second half of 2026. I now hand over to Yannis to briefly review the economics of our partnership with AstraZeneca. Yannis Morel: Thank you, Sonia. As a reminder, under our monalizumab partnership with AstraZeneca, we have received to date $450 million. And the additional potential milestone in the agreement are up to $825 million together with double digit royalties outside Europe and 50% profit sharing in Europe. Turning to Slide 15. I will move now to our next generation ADC pipeline. Beyond IPH4.5 thousand we are using our internal capabilities and technology to build a broad portfolio of differentiated ADC candidates. Turning to slide 16. Leveraging our antibody discovery and engineering expertise, expertise, we have built a comprehensive ADC platform to develop a portfolio of next generation ADCs designed to overcome the limitation of the current ones. Building on IPH4.5 thousand linker, which stability in patients is demonstrated by our emerging clinical data we are developing a drug candidate portfolio around 3 approaches. First, dual targeted bispecifics ADCs to address tumor antigen heterogeneity and to expand addressable indication compared to single tumor antigen targeting. Second, bispecific ADCs with enhanced internalization to unlock the activity in antigen low expressing tumors. And finally, dual payload ADCs using complementary mechanism of action to overcome resistance. I now hand over to Frederic our financial results. Frederic Lombard: Thank you, Yanis. I will now provide a brief overview of our financial position for the first half of 2026. Turning to Slide 18. So as of June 30, 2026, our cash equivalent and financial assets amounted to €21.4 million. That balance does not include the $75 million, Sobi upfront payment equivalent to €65 million, nor the proceeds from the €30 million equity offering. The offering represents €30 million on gross proceeds or €28 million in expected net proceeds. Primary use of proceeds is the continued clinical development of IPH4.5 thousand the advancements of our preclinical ADC portfolio, and as well as general corporate purposes. Together with the Sobe upfront payment, these proceeds are expected to extend our cash runway through the end of the first quarter of 2028. I will now hand over to Jonathan. Jonathan E. Dickinson: Thank you, Frederic. Moving to slide 20, and turning to our key catalysts for the remainder of 2026. For lacutamab, following closing of the strategic partnership with Sobi, TELLOMAK-3 has been initiated. With the first patient planned for the first quarter of 2027. Followed by a planned filing for accelerated approval in the second half of 2027. For IPH4.5 thousand dose escalation enrollment is complete with preliminary antitumor activity and a favorable safety profile observed to date. We will report initial Phase 1 dose escalation data at the EORTC-NCI-AACR meeting on November 18, 2026. And for monalizumab, PACIFIC-9 enrollment is complete. With the Phase 3 readout expected in the second half of this year. So we have 3 important near term catalysts across our focus portfolio. Together with a strengthened financial position that supports our continued execution of these priorities. With that, operator, we are ready to open the call for questions. Operator: We will now begin the question and answer session. If you would like to ask a question, please press star 1 to raise your hand. To withdraw your question, press star 1 again. We ask that you pick up your handset when asking a question to allow for optimum sound quality. If you are muted locally, please remember to unmute your device. Please stand by while we compile the Q&A roster. Your first question comes from the line of Daina Graybosch with Leerink Partners. Your line is open, Daina. Please go ahead. Bill: Good morning, everyone. Congrats on the updates. So just 1 for me. I got Bill on for Daina. So we have seen the prior base ADC show some pretty good activity in the post setting, but it did have some, you know, pretty high heme toxicities. And so can you talk about IPH4.5 thousand stable linker design and what you confidence you will not see the same sort of issues? Thank you. Yannis Morel: Thank you for the question. Maybe, Yanis, you can take that 1. Yeah. Maybe I can start and let Sonia comment? I mean, we have worked on the on the design of the linker, and based on what we have seen at ASCO, published by others with the with their own linker. It seems that the stability of our linker that we have seen in preclinical models, including in nonhuman primates, seems to be translated into the human situation leading to a very limited release of the free payload, which is 1 of the reasons for the systemic pathological toxicity of some AEDCs. Yeah. What we can add is the bicycle data that have been released recently actually stated based on their own data that was seen in the trial. So the instable linker was used as an explanation for the hematologic toxicity in these data set. Sonia Quaratino: Great. Yannis Morel: Thank you. Operator: Your next question comes from the line of Jeet Mukherjee with BTIG. Your line is open, Jeet. Please go ahead. Jeet Mukherjee: Great. Good morning, and thanks for taking the question. So pending, you know, an accelerated approval there, could you speak to the potential for front line off label use for lacutamab in Sezary Syndrome? Given that seems to be the case with mogolizumab? And I have a follow-up question. Jonathan E. Dickinson: Yeah. Maybe I would take that question, Jeet. So our expectation is that lacutamab will be listed in the NCCN guidelines following the accelerated approval for both Sezary Syndrome and for mycosis fungoides. I think with that listing, it seems to leave it open for physicians to be able to use the product across the different lines of therapy. So our expectation based on the safety profile of lacutamab, which is pretty benign, We expect that you will see some off label usage in the first line setting. And so, yes, I mean, I think there is an expectation that you will see that. And, also, despite the fact that the accelerated approval will be in Sezary Syndrome, There will also be an expectation based on the potential listing in the NCCA guidelines for mycosis fungoides that you will also see usage in MF. Hopefully, answers your question. Jeet Mukherjee: Great. I appreciate that. Maybe just 2 other quick follow ups. Just any initial thoughts on pricing Do you think you could price at a premium to mogolizumab? And then separately, on Pacific 9, in terms of just the update format anticipate perhaps a press release at minimum from AstraZeneca. But will Innate have their own press release and analyst call as well? Thank you. Jonathan E. Dickinson: Yeah. So in terms of pricing, we have completed pricing research in the US, which was conducted by ZS Associates. And what we were able to establish with US payers was that we can price lacutamab between $500 thousand and $650 thousand per patient per annum. And that will be supported by our clinical data in the NCCN listing. So there is an expectation here that you would be able to achieve premium pricing, particularly in an indication like Sezary Syndrome, with a relatively low incidence. And then be able to carry that forward into the mycosis fungoides indication, which is a larger indication, but still an orphan disease. So that is pricing. So and then with respect to Pacific 9, you are correct. The expectation is that there will be a press release from AstraZeneca when the results are available, and we would also look to press release that as well and potentially do some calls following the availability of that primary endpoint data. Great. Thank you. Hopefully, that answers the question. Operator: The next question will be read by Stephanie Cornen. Stephanie, please go ahead. Stephanie Cornen: Yes. So we have a question from Clément Steiert from Stifel. The first question is, as dose escalation and cohort expansion enrollment are now complete, should we expect the initial ENA data sets to be primarily a safety pharmacology update? Or mature enough to inform subsequent development decision. So, Sonia, maybe you can take that question. Sonia Quaratino: Yeah. Yeah, the question is almost the answer. So this is out of 11 different indications and 76 patients, so we are expecting to see relevant and informative safety data. And we are also expecting response data from patients, and this will inform our next steps. We need to fully understand the data and we will review and disclose that as proposed on the in our meeting. Thank you. Stephanie Cornen: And there is another question. With the strengthened balance sheet following the recent financing, how far along the development path could you advance IPH4.5 thousand on your own. Frederic Lombard: So, maybe Frederic can take that. Jonathan E. Dickinson: I think you are all aware that we did a small raise of €30 million a couple of weeks ago. The rationale behind that equity raise was to be able to progress seamlessly into the next steps for IPH4.5 thousand So we are well positioned now to be able to move into the next steps, whatever that will be, and will dictate what that is: whether it is dose optimization, and we are equipped to be able to do that. If we would need to broaden the program, if the data supports going to potentially additional tumor types, then that would require additional funding to be able to conduct multiple dose optimizations across different tumor types. But at least for the initial steps, we are funded to be able to take those steps and take the product forward seamlessly into dose optimization. Hopefully, that answers the question again. Operator: We have now reached the end of the Q&A session. I will turn the call back to Jonathan E. Dickinson, CEO, for closing remarks. Jonathan E. Dickinson: So thank you very much everybody for joining us today for our update and following our H1 results. We look forward to updating you as we progress through the important catalysts that we outlined today, which come across the remainder of the year. So thank you for your time, and see you soon. Operator: This concludes today's call. Thank you for attending. You may now disconnect. Before you buy stock in Innate Pharma, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Innate Pharma wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $412,074!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,314,319!* Now, it’s worth noting Stock Advisor’s total average return is 932% — a market-crushing outperformance compared to 209% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors. See the 10 stocks » *Stock Advisor returns as of September 17, 2026. This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Innate Pharma (IPHA) Q2 2026 Earnings Call Transcript was originally published by The Motley Fool

New strategic partnership with Sobi to advance lacutamab is effective, with a $75 million upfront payment; TELLOMAK-3 phase 3 initiated with FPI expected in Q1 2027 €30 million equity financing completed to primarily support IPH4502 and preclinical ADC portfolio IPH4502 Phase 1 dose escalation and cohort enrichment enrollment completed, with initial data to be presented at ENA 2026 PACIFIC-9 Phase 3 readout for monalizumab, led by AstraZeneca, expected in H2 2026 Cash position of €21.4 million1 as of June 30, 2026 Anticipated cash horizon until the end of Q1 2028, taking into account the initial payment of $75 million expected from the completion of the transaction with Sobi and the proceeds from the €30 million capital increase Conference call to be held today at 2:00 p.m. CEST / 8:00 a.m. ET MARSEILLE, France, September 17, 2026--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today reported its consolidated financial results for the six months ended June 30, 2026. The consolidated financial statements are attached to this press release. "2026 continues to be an important year of execution for Innate, marked by our strategic partnership with Sobi and the strengthening of our financial position," said Jonathan Dickinson, CEO of Innate Pharma. "With the TELLOMAK-3 Phase 3 study initiated, we are targeting the first patient in the study in Q1 2027 as we work toward a filing for accelerated approval in Sézary syndrome. Looking ahead, we will present Phase 1 data from IPH4502 at ENA 2026 and expect the PACIFIC-9 Phase 3 readout for monalizumab by year-end, as we remain focused on delivering value for patients and shareholders." Pipeline highlights: Lacutamab (anti-KIR3DL2 antibody), partnered with Sobi: Cutaneous T-Cell Lymphoma In August 2026, Innate Pharma entered into a strategic partnership with Sobi to license lacutamab in T-cell lymphoma (Link PR). The partnership is intended to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T-cell lymphoma (CTCL), a key step toward filing for accelerated approval of lacutamab in Sézary syndrome, a subtype of CTCL. On September 16, Innate Pharma announced closing of the transaction under the partnership agreement, following expiration of the anti-trust waiting periods and completion of other conditions (Link PR). This triggers a USD 75 million upfront payment and marks the initiation of the TELLOMAK-3 confirmatory Phase 3 study, with first patient expected in Q1 2027. Under the agreement, Innate is conducting the TELLOMAK-3 Phase 3 confirmatory trial in cutaneous T-cell lymphoma. The TELLOMAK-3 study will subsequently support applications for full approvals in key jurisdictions in Sézary syndrome and mycosis fungoides, the most common subtype. Sobi will receive exclusive global rights to commercialize lacutamab upon potential accelerated approval and will be eligible to assume full global development rights following positive Phase 3 results. Under the terms of the agreement, Sobi will pay Innate Pharma USD 75 million, payable on closing. Innate will be eligible to receive up to a further USD 40 million in respect of near-term development milestones connected to Sézary syndrome. Additionally, Innate will be eligible to receive up to USD 465 million related to the option for Sobi to get full development rights and to future regulatory and commercial milestones. Innate will be eligible to receive tiered double-digit royalties on net sales. In February 2025, the FDA granted Breakthrough Therapy Designation to lacutamab for relapsed or refractory Sézary syndrome based on TELLOMAK Phase 2 results demonstrating encouraging efficacy and a favorable safety profile in patients with Sézary syndrome, heavily pretreated, post-mogamulizumab. Breakthrough Therapy Designation is intended to accelerate the development and regulatory review in the U.S. of drugs that are intended to treat a serious condition and that have shown encouraging early clinical results, which may demonstrate substantial improvement on a clinically significant endpoint over available medicines. Lacutamab has also received Fast Track designation from the FDA, PRIME designation from the EMA and orphan drug status in both the United States and Europe. Peripheral T-Cell Lymphoma (PTCL) The investigator-sponsored Phase 2 KILT (anti-KIR in T-Cell Lymphoma) trial, led by the Lymphoma Study Association (LYSA), evaluating lacutamab in combination with GEMOX (gemcitabine and oxaliplatin) versus GEMOX alone in patients with KIR3DL2-expressing relapsed/refractory PTCL has ended recruitment. IPH4502 (Nectin-4 exatecan ADC): In July 2026, Innate announced completion of dose-escalation and backfill enrollment in the ongoing Phase 1 study of IPH4502, with 76 patients enrolled across multiple tumor types known to express Nectin-4. Preliminary anti-tumor activity has been observed in heavily pre-treated patients, including objective responses in urothelial cancer following prior enfortumab vedotin, as well as in NSCLC and HNSCC. A favorable safety profile has been observed to date, with limited hematological toxicity. Initial Phase 1 dose-escalation data will be presented at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026) on November 18, 2026. Monalizumab (anti-NKG2A antibody), developed in collaboration with AstraZeneca: PACIFIC-9 is an AstraZeneca-sponsored Phase 3 study evaluating durvalumab in combination with monalizumab or oleclumab in patients with unresectable Stage III NSCLC who have not progressed following platinum-based chemoradiation therapy (CRT). Enrollment in the trial is complete, and data readout is expected in H2 2026. The Phase 3 program is supported by clinical findings from the Phase 2 COAST study, in which the combination of durvalumab and monalizumab suggested prolonged progression-free survival compared with durvalumab alone. IPH5201 (anti-CD39 antibody, developed in collaboration with AstraZeneca): The Phase 2 MATISSE study evaluating IPH5201 in combination with durvalumab and platinum-based chemotherapy in resectable NSCLC is ongoing. Encouraging results from a pre-planned interim analysis presented at AACR 2026 showed an overall pathological complete response rate of 27.5%, with higher response rates observed in patients with PD-L1-positive tumors. Following the interim analysis, MATISSE continues enrollment in the PD-L1 ≥1% patient population. Preclinical ADC pipeline For its preclinical ADC portfolio, Innate is leveraging its proprietary linker technology, in clinical development through IPH4502. Innate’s next-generation ADC approaches include bispecific ADCs designed to address tumor antigen heterogeneity, approaches aimed at enhancing internalization to unlock activity in tumors with low target expression, and dual-payload approaches intended to overcome payload resistance. Post period events and Corporate Update: In August 2026, Innate Pharma announced the appointment of Markus Jensen, 57, as Chief Medical Officer and member of the Executive Leadership Team, effective September 1, 2026. He succeeds Sonia Quaratino and oversees the Company’s clinical development activities as Innate prepares to advance lacutamab into Phase 3 and continues development of IPH4502. Markus Jensen joined Innate Pharma in 2024 as head of clinical pharmacology and has served as global clinical lead for Company key programs, including IPH4502. He brings more than 25 years of experience spanning clinical medicine, academic research and the pharmaceutical industry. Prior to joining Innate, he held leadership positions at Bayer for more than 16 years, with a particular focus on oncology and clinical development. He holds a medical degree from the University of Cologne and is double board certified by Ärztekammer Nordrhein in Internal Medicine and Clinical Pharmacology. On August 18, 2026, Innate completed a capital increase without preferential subscription consisting of a private placement of 17,647,059 new ordinary shares of the Company for aggregate gross proceeds to the Company of an approximately €30 million. Together with the $75 million upfront payment, the proceeds of the private placement are expected to extend the Company’s projected cash runway through end of Q1 2028. As of June 30, 2026, the balance available under our April 2023 sales agreement under the At-The-Market program remains at $75 million. Financials highlights for the first half of 2026: The key elements of Innate’s financial position and financial results as of and for the six-month period ended June 30, 2026 are as follows: Cash, cash equivalents, short-term investments and financial assets amounting to €21.4 million (€m) as of June 30, 2026 (€44.8m as of December 31, 2025). As of June 30, 2026, financial liabilities amount to €20.2m (€22.6m as of December 31, 2025). This change is mainly due to loan repayments. Revenue and other income amounted to €5.7m in the first half of 2026 (€4.9m in the first half of 2025) and mainly comprised of: Operating expenses are €24.7m in the first half of 2026 (€30.3m in the first half of 2025), of which 68.4% (€16.9m) are related to R&D. A net financial loss of €0.6m in the first half of 2026 (profit for €4.1m in the first half of 2025). This change is mainly due to an unfavorable variation in net foreign exchange gain with its unfavorable impact on the collaboration liabilities recorded during the first half of 2026 in connection with the change in the dollar exchange rate and an unfavorable variation in income resulting from financial assets and fair value revaluation due to an unfavorable effect of investment rates recorded on the financial markets. A net loss of €19.6m for the first half of 2026 (net loss of €21.3m for the first half of 2025). The table below summarizes the IFRS consolidated financial statements as of and for the six months ended June 30, 2026, including 2025 comparative information. About Innate Pharma Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise in antibody engineering and innovative target identification, Innate Pharma is developing innovative and differentiated next-generation antibody therapeutics. Innate Pharma is advancing a portfolio of differentiated potential first- and/or best-in-class assets, focused on areas of high unmet medical need. Its proprietary pipeline is centered on antibody-drug conjugates (ADCs), led by IPH4502, a differentiated Nectin-4 ADC in clinical development for solid tumors, and supported by a preclinical portfolio of next-generation ADC candidates. In parallel, Innate is advancing two partnered late-stage assets: lacutamab, developed with Sobi for T-cell lymphomas, and monalizumab, developed with AstraZeneca for non-small cell lung cancer. Innate Pharma has established collaborations with leading biopharmaceutical companies, including Sobi, Sanofi and AstraZeneca, as well as renowned academic and research institutions, to advance innovation in immuno-oncology. Headquartered in Marseille, France, Innate Pharma is listed on Euronext Paris and Nasdaq in the US. Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X. Information about Innate Pharma shares ISIN code: FR0010331421Ticker code: Euronext Paris: IPH | Nasdaq: IPHALEI: 9695002Y8420ZB8HJE29 Disclaimer on forward-looking information and risk factors This press release contains certain forward-looking statements, including those within the meaning of applicable securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. All statements other than present and historical facts and conditions contained in this press release, including statements regarding the future results of operations and financial position, business strategy, plans and the Company’s objectives for future operations, are forward-looking statements. These are based on the management’s current beliefs, expectations and assumptions about future events, conditions and results and on information currently available to the management. When used in this press release, certain words, including "anticipate," "plan," "believe," "can," "could," "estimate," "project," "expect," "may," "might," "potential," "should," "will," or the negative of these and similar expressions, identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, enrolment, results and other milestones of its preclinical trials, the Company’s reliance on third parties to manufacture its product candidates, the Company’s commercialization efforts and the Company’s continued ability to raise capital to fund its development and product trials. For additional discussion of risks and uncertainties, which could cause the Company's actual results, financial condition, performance or achievements to differ materially from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority ("AMF"), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission ("SEC"), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2025, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company’s website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame or at all. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country. Summary of Interim Condensed Consolidated Financial Statements and Notes as of JUNE 30, 2026 Revenue and other income The following table summarizes operating revenue for the periods under review: Revenue from collaboration and licensing agreements Revenue from collaboration and licensing agreements increased by €1.4 million, to €3.1 million for the six months ended June 30, 2026, as compared to revenues from collaboration and licensing agreements of €1.7 million for the six months ended June 30, 2025. These revenues mainly result from the partial or entire recognition of the proceeds received pursuant to the agreements with AstraZeneca and Sanofi. They are recognized when the entity's performance obligation is met. They are recognized at a point in time or spread over time according to the percentage of completion of the work that the Company is committed to carry out under these agreements. The evolution for the first half of 2026 is mainly due to: (i) Since December 31, 2025, the revenue from collaboration and licensing agreements for monalizumab has been fully recognized. Therefore, no revenue is recognized for the six months ended June 30, 2026, as compared to €0.1 million for the six months ended June 30, 2025. (ii) No revenue related to IPH5201 were generated during the six months ended June 30, 2026 as during the six months ended June 30, 2025. As a reminder, the revenue is related to the milestone payment received from AstraZeneca following the signature on June 1, 2022 of an amendment to the initial contract signed in October 2018. This amendment sets the terms of the collaboration following AstraZeneca’s decision to advance IPH5201 to a Phase 2 study.The Company will conduct the study. Both parties will share the external cost related to the study and incurred by the Company and AstraZeneca will provide products necessary to conduct the clinical trial.Revenue from invoicing of research and development costs for the six months ended June 30, 2026 was 0.4 million compared to 0.9 million for the six months ended June 30, 2025, or a decrease of (0.5) million. (iii) No revenue were generated for the license and collaboration agreement signed with Sanofi in 2016 for the six months ended June 30, 2026, as well as for the six months ended June 30, 2025. On April 23, 2025, the Company announced that, in alignment with both company's current strategic priorities, Sanofi and Innate agreed to terminate the 2016 Agreement as it relates to SAR’579/IPH6101 (CD123 ANKET®). Innate regained the rights to SAR’579/IPH6101 in July 2025. Data from the Sanofi-led Phase 1/2 study and Phase 2 preliminary dose expansion of the trial have been transferred to Innate. Otherwise, Sanofi announced deprioritization of SAR’514, a trifunctional anti-BCMA NK-cell engager and retains exclusive development and commercialization rights, and the license terms remain unchanged. It has not triggered any milestone payments as of June 30, 2026. (iiii) Revenue related to the research collaboration and licensing agreement signed with Sanofi in 2022 remained constant over the period, with revenue amounting to €0.2 million for the first half of 2026, as for the first half of 2025. As previously disclosed, In December 2022, the Company entered into a research collaboration and license agreement with Genzyme Corporation, a wholly owned subsidiary of Sanofi ("Sanofi"), under which the Company granted Sanofi an exclusive license to Innate’s B7-H3 ANKET® program and options for two additional targets.In March 2023, Innate Pharma received an upfront payment of €25 million under its research, collaboration and license agreement with Sanofi. This amount consisted of €18.5 million relating to the exclusive license to the B7-H3 technology, which was recognized in profit or loss in June 2023; €1.5 million relating to research activities to be performed over a three-year period, recognized as revenue on a straight-line basis through November 2026; and €5 million relating to the two additional license options, recognized as contract liabilities until their expiration or until the options are exercised.In December 2023, Sanofi exercised one of its license options for an ANKET® program, resulting in the recognition of €2.5 million in revenue and the payment of a €15 million milestone, of which €13.3 million related to the license was recognized immediately in revenue and €1.7 million related to research activities. These research activities were discontinued following the termination of the agreement in October 2024, which led to the full recognition of the €1.7 million in revenue in 2024. As a result, Innate regained the rights to the IPH67 program, while Sanofi retains a right to compensation on any potential future revenues.On January 24, 2026, following the expiration of the deadline to exercise the license option on an identified target, the revenue of €2.5 million has been fully recognized. Sanofi still has a right on a non-exclusive license option for an additional target, exercisable up to January 24, 2028. This option is not linked with any other revenue. Government financing for research expenditures Government financing for research expenditures decreased by €0.6 million, or 20.1%, to €2.5 million for the six months ended June 30, 2026 as compared to €3.2 million for the six months ended June 30, 2025. This change is mainly due to a €0.8 million decrease in the research tax credit due to a decrease in eligible subcontracting expenses. Operating expenses The table below presents our operating expenses for the six months periods ended June 30, 2026 and June 30, 2025: Research and development expenses Research and development ("R&D") expenses decreased by €3.6 million, or 17.8%, to €16.9 million for the six months ended June 30, 2026, as compared to €20.5 million for the six months ended June 30, 2025, representing a total of 68.4% and 67.8% of the total operating expenses, respectively. R&D expenses include direct R&D expenses (subcontracting costs and consumables), depreciation and amortization, personnel expenses and other expenses. Direct R&D expenses decreased by €1.5 million, or 15.3%, to €8.2 million for the six months ended June 30, 2026, as compared to €9.7 million for the six months ended June 30, 2025. This variation is mainly explained by a €1.0 million decrease in expenses related to the phasing of studies (maturity of clinical studies on lacutamab and IPH5201, discontinuation of preclinical studies partially offset by the ramp-up of IPH4502, our antibody-drug conjugate (ADC)). The change in expenses related to clinical programs is attributable to: (i) an increase of €0.5 million for IPH4502, related to the completion of patient enrollment in the dose-escalation phase of the Phase 1 study; (ii) a decrease of €0.5 million for the lacutamab program, as clinical studies are reaching completion; (iii) a decrease of €1.0 million in the IPH5201 program, as recruitment for Cohort 2 was less advanced than that for Cohort 1 whose recruitment was finalized in the first half of 2025. Additionally, as of June 30, 2026, collaboration liabilities related to monalizumab and the agreements signed with AstraZeneca in April 2015, October 2018, and September 2020 amounted to €39.6 million, as compared to collaborations liabilities to €38.2 million as of December 31, 2025. This €1.4 million increase mainly results from due to exchange rate fluctuations observed during the period for the euro-dollar exchange rate. Personnel and other expenses allocated to R&D decreased by €2.2 million, or 20.0%, to €8.6 million for the six months ended June 30, 2026, as compared to an amount of €10.8 million for the six months ended June 30, 2025 due to a reduction in personnel expenses of €2.7 million, resulting from a reduction in the R&D workforce (from 133 to 92 employees), partially offset by a €0.7 million increase in other expenses, corresponding to a provision for risks and charges.. General and administrative expenses General and administrative expenses decreased by €2.0 million, or 20.2%, to €7.8 million for the six months ended June 30, 2026, as compared to general and administrative expenses of €9.8 million for the six months ended June 30, 2025. General and administrative expenses represented a total of 31.6% and 32.2% of the total operating expenses for the six months ended June 30, 2026 and June 30, 2025, respectively. Personnel expenses includes the compensation paid to our employees. They amounted €3.2 million for the six months ended June 30, 2026, as compared to €4.8 million for the six months ended June 30, 2025. The decrease of €1.5 million is primarily due to employees reduction (29 employees for the six months ended June 30, 2026 vs. 42 for the six months ended June 30, 2025). Non-scientific and consulting fees mainly consist of fees for statutory auditors, accountants, legal advisors, and recruitment. This item decreased by €0.2 million, or 15.2%, to €1.2 million for the first half of 2025, compared to €1.4 million for the first half of 2024. The decrease is mainly due to the suspension of the "At the Market" program on the Nasdaq. Other expenses decreased by €0.2 million, primarily in connection with the Director & Officer (D&O) insurance policy. Financial income (loss), net We recognized a net financial loss of €0.6 million in the six months ended June 30, 2026 as compared to €4.1 million in the six months ended June 30, 2025. This variance of €2.5 million mainly results from (i) a favorable variation in net foreign exchange gain increasing by €(3.9) million for the first half of 2026 with its favorable impact on the collaboration liabilities recorded during the first half of 2026 in connection with the change in the dollar exchange rate and (ii) an unfavorable variation of €0.9 million in income resulting from financial assets and fair value revaluation due to an unfavorable effect of investment rates recorded on the financial markets. Balance sheet items Cash, cash equivalents, short-term investments and non-current financial assets amounted to €21.4 million as of June 30, 2026, as compared to €44.8 million as of December 31, 2025. Net cash as of June 30, 2026 amounted to €0.1 million (€25.5 million as of December 31, 2025). Net cash is equal to cash, cash equivalents and short-term investments less current financial liabilities. The Company also has bank borrowings of €20.1m, including €12.8m of State Guaranteed Loans ("Prêts Garantis par l’Etat") as of June 30, 2026 and €7.3m loans subscribed with Société Générale for the construction of its head office as well as €0.1m of lease liabilities. The other key balance sheet items as of June 30, 2026 are: A receivable of €4.1 million from the French State, including €2.5 million for the research tax credit for the first half of 2026 and €1.6 million for VAT credits for the first half of 2026. Advances granted to suppliers to primarily finance ongoing clinical activities, amounting to €2.3 million. Collaboration debt of €39.6 million (of which €30.6 million is recorded as "Collaboration Debt – Non-Current Part"), corresponding to the Company’s commitment to co-financing the monalizumab program with AstraZeneca. Shareholders’ equity amounting to (40.5) million euros, including the net loss for the first half of 2026 of 19.6 million euros. Cash-flow items As of June 30, 2026, cash and cash equivalents amounted to €6.5 million, compared to €28.1 million as of December 31, 2025, corresponding in a decrease of €21.6 million. The net cash flow used during the period under review mainly results from the following: Net cash flow generated from operating activities of €21.0 million for the six months ended June 30, 2026 as compared to net cash flows used by operating activities of €31.2 million for the six months ended June 30, 2025. Net cash flow from operating activities for the first half of 2026 includes the receipt of the Research Tax Credit (CIR) due for fiscal year 2025, amounting to €6.2 million. Excluding this receipt, cash flow from operating activities for the first half of 2026 is down by €3.9 million compared to the first half of 2025. This is primarily due to lower net payments to suppliers related to reduced operating expenses and changes in collaboration debt. Net cash flow from investing activities of €2.0 million for the six months ended June 30, 2026 mainly composed of a disposal of current financial instruments to meet cash requirements. Net cash flow used in investing activities of €7.0 million for the first half of 2025 was mainly comprised of a disposal of a current financial instrument and reinvested up to 4.0 million euros in term deposits in order to secure and diversify investments. Net cash flow in financing activities for the six months ended June 30, 2026 was €2.4 million as compared to net cash flow used in financing activities of €10.5 million for the six months ended June 30, 2025, consumptions mainly related to repayments of financial liabilities for €2,4 million (€4,4 million for the six month ended June 30, 2025) as the company benefited from a deferral of loan repayments related to the second quarter of 2026 for an amount of €2.1 million. As a reminder, the first 2025 semester cash flow included the investment for a net amount of €14,9 million received from Sanofi. Post period events On August 10, 2026, Innate Pharma S.A. and Swedish Orphan Biovitrum AB (publ) (Sobi®) announced that they have entered a strategic partnership. Under the terms of the agreement, Sobi will pay Innate Pharma USD 75 million, payable on closing. Innate will be eligible to receive up to a further USD 40 million in respect of near-term development milestones connected to Sézary syndrome. Additionally, Innate will be eligible to receive up to USD 465 million related to the option for Sobi to get full development rights and to future regulatory and commercial milestones. Innate will be eligible to receive tiered double-digit royalties on net sales. This partnership will enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T-cell lymphoma (CTCL), a key step toward filing for accelerated approval of lacutamab in Sézary syndrome, a subtype of CTCL. Under the agreement, Innate will conduct the TELLOMAK-3 Phase 3 confirmatory trial in cutaneous T-cell lymphoma, supporting a planned accelerated approval filing in Sézary syndrome. The planned TELLOMAK-3 study will subsequently support applications for full approvals in key jurisdictions in Sézary syndrome and mycosis fungoides, the most common subtype. Sobi will receive exclusive global rights to commercialize lacutamab upon potential accelerated approval and will be eligible to assume full global development rights following positive Phase 3 results. Closing of the transaction is subject to closing conditions that have be fulfilled on September 16, 2026. On August 18, 2026, the company carried out a capital increase of €30 million though the issuance of 17,647,059 new Company ordinary shares at a price of €1.70 per new Ordinary Share. Nota The interim condensed consolidated financial statements for the six-month period ended June 30, 2026 were established in accordance with IAS 34 standard adopted by European Union and as issued by the International Accounting Standards Board (IASB). They have been subject to a limited review by our Statutory Auditors and were approved by the Board of Directors of the Company on September 16, 2026. They will not be submitted for approval to the general meeting of shareholders. Risk factors Risk factors identified by the Company are presented in the item 3.D of the annual report filed with the SEC (20-F), on April 1, 2026 (SEC Accession No. 0001598599-26-000005). The main risks and uncertainties the Company may face in the six remaining months of the year are the same as the ones presented in the annual report available on the internet website of the Company. Of note, the risks that are likely to arise during the remaining six months of the current financial year could also occur during subsequent years. Related party transactions: Transactions with related parties during the periods under review are disclosed in Note 18 to the interim condensed consolidated financial statements for the period ended June 30, 2026 prepared in accordance with IAS 34. View source version on businesswire.com: https://www.businesswire.com/news/home/20260916318613/en/ Contacts Stéphanie CornenVP, Investor Relations & Corporate [email protected] Investor [email protected] [email protected]

Interested in Innate Pharma S.A. Sponsored ADR? Here are five stocks we like better. Innate Pharma strengthened its finances through a Sobi partnership for lacutamab, including a $75 million upfront payment, and a €30 million equity financing. The company expects its cash runway to extend through the end of Q1 2028. Lacutamab’s phase III TELLOMAK-3 trial has begun, with enrollment expected in Q1 2027 and a potential accelerated-approval filing for Sézary syndrome planned for the second half of 2027. Sobi holds potential global commercialization and development rights under the agreement. The company expects key clinical updates in the second half of 2026, including a PACIFIC-9 phase III readout for monalizumab and initial phase I data for IPH4502, an antibody-drug conjugate that has shown preliminary responses in several heavily pretreated solid-tumor populations. Innate Pharma (NASDAQ:IPHA) said its first-half 2026 developments included the closing of a strategic partnership with Sobi for lacutamab, completion of dose-escalation enrollment for IPH4502, and completed enrollment in the PACIFIC-9 phase III study of monalizumab. Chief Executive Officer Jonathan Dickinson said the Sobi transaction became effective following its closing and included a $75 million upfront payment. Combined with a €30 million equity financing, the company expects the funding to extend its projected cash runway through the end of the first quarter of 2028. → Could Dave & Buster’s Capitulation Signal the Bottom Is Finally In? Lacutamab, Innate’s anti-KIR3DL2 antibody, is being developed for cutaneous T-cell lymphoma. The company said it has initiated the TELLOMAK-3 confirmatory phase III trial, with the first patient expected to be enrolled in the first quarter of 2027. The study includes a confirmatory cohort in Sézary syndrome and a registrational cohort in mycosis fungoides, according to Chief Medical Officer Markus Jensen. Innate plans to seek accelerated approval in Sézary syndrome in the second half of 2027 based on existing phase II TELLOMAK data once the phase III study is underway. → SpaceX Defies Gravity With a Nasdaq-100 Double-Weighting Boost Jensen said lacutamab has received FDA Breakthrough Therapy designation for relapsed or refractory Sézary syndrome, as well as FDA Fast Track designation, European Medicines Agency PRIME designation, and orphan-drug designations in the U.S. and Europe. Under the Sobi agreement, Innate will conduct the phase III trial and file for potential accelerated approval. If the product receives accelerated approval, Sobi would receive exclusive global commercialization rights. Following positive phase III results, Sobi could obtain full global development rights. $75 million upfront payment Up to $40 million in near-term Sézary syndrome milestones Up to an additional $465 million tied to development-rights options and future regulatory and commercial milestones Tiered double-digit royalties on future net sales → Running on Empty: 3 Energy Plays for Europe's Deep Freeze During the question-and-answer session, Dickinson said the company expects lacutamab could be included in National Comprehensive Cancer Network guidelines after a potential accelerated approval. He said Innate expects physicians may use the treatment off-label in earlier lines of therapy and in mycosis fungoides, though the initial accelerated approval filing would be for Sézary syndrome. Dickinson also said pricing research conducted with U.S. payers indicated potential annual pricing of between €500,000 and €625,000 per patient, supported by the company’s clinical data and a potential NCCN listing. Innate completed phase I dose escalation and cohort-enrichment enrollment for IPH4502, its Nectin-4 exatecan antibody-drug conjugate for advanced solid tumors. The company reported preliminary antitumor activity, including objective responses in heavily pretreated patients with urothelial cancer after prior enfortumab vedotin treatment, as well as in non-small cell lung cancer and head and neck cancer. The company said it has observed a favorable safety profile to date, including limited hematological toxicity. Jensen said approximately 15 patients have been enrolled in each of the post-enfortumab vedotin urothelial cancer and head and neck cancer cohorts, while enrollment in the non-small cell lung cancer cohort was lower. Management attributed the observed safety profile in part to the molecule’s stable proprietary linker, which it said may limit the release of free payload associated with systemic toxicity in some antibody-drug conjugates. Innate plans to present initial phase I dose-escalation data at the EORTC-NCI-AACR meeting in Barcelona in November. Management referenced November 18 during prepared remarks, while Jensen referenced November 26 during his presentation. Jensen said the dataset spans 11 indications and 76 patients and is expected to provide both safety and response information to guide next development steps. Dickinson said the recent equity financing should allow Innate to move into dose optimization, while expansion into multiple additional tumor types could require further funding. Enrollment has been completed in PACIFIC-9, a randomized phase III trial of monalizumab in unresectable stage III non-small cell lung cancer. The study enrolled 1,051 patients who had not progressed following definitive platinum-based concurrent chemoradiotherapy. PACIFIC-9 compares durvalumab plus oleclumab, durvalumab plus monalizumab, and durvalumab plus placebo, with progression-free survival as the primary endpoint. Innate continues to expect a phase III readout during the second half of 2026. Chief Operating Officer Yannis Morel said Innate has received €450 million to date under its monalizumab partnership with AstraZeneca. The agreement also includes up to €825 million in additional potential milestones, double-digit royalties outside Europe, and 50% profit sharing in Europe. Chief Financial Officer Frédéric Lombard said Innate had €21.4 million in cash equivalents and financial assets as of June 30, 2026. That balance excluded the Sobi upfront payment, which the company valued at approximately €65 million, and proceeds from the equity offering. The €30 million offering is expected to generate approximately €28 million in net proceeds. Innate said the funds are intended to support continued IPH4502 clinical development, advancement of its preclinical antibody-drug conjugate portfolio, and general corporate purposes. Innate Pharma SA is a biotechnology company headquartered in Marseille, France, focused on developing immunotherapies for cancer. Founded in 1999, the company uses its expertise in the biology of natural killer cells and other components of the innate immune system to develop antibody-based treatments designed to help the immune system recognize and attack cancer cells. Innate Pharma's pipeline includes lacutamab, an investigational antibody targeting KIR3DL2 for certain forms of cutaneous T-cell lymphoma and other T-cell malignancies. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. The article "Innate Pharma Q2 Earnings Call Highlights" was originally published by MarketBeat. View MarketBeat's top stocks for September 2026.

MARSEILLE, France, September 10, 2026--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), today announced that the Company will hold a conference call on Thursday, September 17, 2026 at 2:00 p.m. CEST / 8:00 a.m. EDT, to provide a business update for the first half of 2026. Participants in the call will be: Jonathan Dickinson, Chief Executive Officer Markus Jensen, Vice President, Chief Medical Officer Yannis Morel, Executive Vice President, Chief Operating Officer Frédéric Lombard, Senior Vice President, Chief Financial Officer Event Details Date and time: September 17, 2026, at 2:00 p.m. CEST / 8:00 a.m. EDT Webcast link: Click here Conference call link: Click here This information is also available on the Investors section of the Innate Pharma website, www.innate-pharma.com. A replay of the webcast will be available on the Company website for 90 days following the event. About Innate Pharma Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise on antibody engineering and innovative target identification, Innate Pharma is developing innovative and differentiated next generation antibody therapeutics. Innate Pharma is advancing a portfolio of differentiated potential first- and/or best-in-class assets, focused on areas of high unmet medical need. Its proprietary pipeline is centered on antibody-drug conjugates (ADCs), led by IPH4502, a differentiated Nectin-4 ADC in clinical development for solid tumors, and supported by a preclinical portfolio of next-generation ADC candidates. In parallel, Innate is advancing two partnered late-stage assets: lacutamab, developed with Sobi for cutaneous T-cell lymphomas, and monalizumab, developed with AstraZeneca for non-small cell lung cancer (NSCLC). Innate Pharma has established collaborations with leading biopharmaceutical companies, including Sobi, Sanofi and AstraZeneca, as well as renowned academic and research institutions, to advance innovation in immuno-oncology. Headquartered in Marseille, France, Innate Pharma is listed on Euronext Paris and Nasdaq in the US. Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X. Information about Innate Pharma shares ISIN code: FR0010331421Ticker code: Euronext Paris: IPH | Nasdaq: IPHALEI: 9695002Y8420ZB8HJE29 Disclaimer on forward-looking information and risk factors For a discussion of risks and uncertainties, please refer to the Risk Factors ("Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority ("AMF"), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission ("SEC"), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2025, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company’s website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country. View source version on businesswire.com: https://www.businesswire.com/news/home/20260909069077/en/ Contacts Stéphanie CornenVP, Investor Relations & Corporate [email protected] Investor [email protected] [email protected]

This article first appeared on GuruFocus. Equity Raise: $30 million equity raise announced. Strategic Partnership Upfront Payment: $75 million upfront payment from SOBI, plus up to $40 million in near-term milestones. Potential Milestones: Additional $465 million in opt-in regulatory and commercial milestones, plus double-digit tiered royalties on future lacutamab sales. Monolizumab Milestones: Up to $825 million in potential milestones, 50% profit share for Europe, and double-digit royalties on sales outside Europe. Cash Runway: Projected cash runway extended through Q1 2028. Warning! GuruFocus has detected 8 Warning Signs with IPHA. Is IPHA fairly valued? Test your thesis with our free DCF calculator. Release Date: August 14, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Innate Pharma SA (NASDAQ:IPHA) secured a $30 million equity raise, extending its projected cash runway through Q1 2028. The strategic partnership with SOBI, including a $75 million upfront payment and up to $40 million in near-term milestones, enables the initiation of the TELAMAC-3 phase 3 study for lacutamab. IPH 4502, a second-generation Nectin-4 ADC, has shown preliminary clinical activity in post-PADCEF urothelial cancer, non-small cell lung cancer, and head and neck cancer, with a favorable safety profile. The proprietary linker of IPH 4502 has demonstrated stability in patients, supporting the hypothesis of minimized payload release into circulation. The upcoming Pacific-9 study readout for monalizumab, with up to $825 million in potential milestones and a 50% profit share in Europe, represents a significant future value opportunity. The company is advancing a preclinical ADC portfolio with innovative approaches, including bispecific ADCs and dual-payload ADCs, to address tumor heterogeneity and resistance. The $30 million equity raise may dilute existing shareholders, and the company did not provide specific details on the number of patients or follow-up data for IPH 4502 in each indication. The TELAMAC-3 study initiation is subject to conditions, including antitrust clearance, which could delay the timeline. The company has not yet presented the full data set for IPH 4502, and the next development steps are dependent on the results, which are not yet available. The Pacific-9 study primary completion date is not until the end of September, with data expected by year end, leaving uncertainty about the outcome and potential value realization. The company's ability to progress its preclinical ADC portfolio is contingent on the success of IPH 4502, and the timeline for communicating on these programs is not until 2027, indicating a long wait for potential catalysts. The CEO noted that the company is in a competitive space for Nectin-4 ADCs, and the ambiguity around Lilly's program could pose competitive risks. Q: What is the rationale behind the $30 million equity raise, and how does it fit with the recent Sobi partnership?A: Jonathan Dickinson, CEO, explained that the raise is designed to allow seamless progression of IPH 4502 into next development steps following the presentation of dose-escalation data later this year, avoiding a future financing gap. It also funds the advancement of the preclinical ADC portfolio. The Sobi partnership, which provides a $75 million upfront at closing, extends the projected cash runway through Q1 2028, while this raise ensures momentum in the competitive Nectin-4 ADC space. Q: Can you provide more guidance on the number of patients and follow-up for IPH 4502 in the highlighted indications (post-PADCEF bladder, head and neck, and lung)?A: Jonathan Dickinson, CEO, stated that while specific patient numbers per indication were not disclosed, the company expects 10-15 patients at go-forward pharmacological doses in each indication. Since the last patients were recruited in mid-July, follow-up scans are needed, pushing the efficacy data presentation to a medical conference later in the year, which he noted is not ESMO. Q: Given recent Nectin-4 ADC readouts with varying therapeutic indices, why should we be excited about IPH 4502's differentiation?A: Jonathan Dickinson, CEO, highlighted that IPH 4502's proprietary linker benchmarks with the best in the field, minimizing hematological toxicity. The company has achieved dosing levels comparable to other Topo1-based ADCs, and the Lilly dataset validated the approach of targeting Nectin-4 post-PADCEF. Crucially, all urothelial cancer patients in the study had prior PADCEF and most also received Pembro, so any observed activity in this heavily pre-treated, progressing population is considered genuine and encouraging. Q: Is the $30 million raise a bridging funding between now and the Sobi close, or is it for other purposes?A: Jonathan Dickinson, CEO, clarified that the raise is primarily to fund the next steps for IPH 4502 and the preclinical ADC portfolio, not as a bridge. The goal is to present data and immediately proceed with development without interruption. He emphasized the competitive landscape, noting that with Lilly's program facing ambiguity, Innate is close to the front of the pack for Western-based Nectin-4 ADCs and wants to maintain speed. Q: When will we get a full picture of IPH 4502's development pathway and see the pipeline molecules?A: Jonathan Dickinson, CEO, stated that the full data set for IPH 4502 will be presented at a medical conference later in 2026, which will dictate the next tumor types to pursue. While activity has been seen in urothelial, head and neck, and non-small cell lung cancer, the complete data will validate these as candidates. For the preclinical ADC portfolio, the company expects to start communicating on those aspects sometime in 2027. Q: Are there expansion opportunities for monalizumab outside of oncology, such as in fibrosis indications like IPF?A: Jonathan Dickinson, CEO, acknowledged the recent publication highlighting monalizumab's potential in fibrosis but stated the company is currently focused on the PACIFIC-9 readout in non-small cell lung cancer, which is the critical gating factor. He reminded that AstraZeneca's license covers oncology indications only, so a fibrosis indication would be outside the collaboration agreement. The company will evaluate other opportunities after seeing PACIFIC-9 results. Q: What would be due upfront to Innate if PACIFIC-9 is positive?A: Jonathan Dickinson, CEO, did not disclose the specific schedule of milestones but reminded that there are up to $400 million in development and regulatory milestones tied to the AstraZeneca collaboration. He noted these follow standard criteria for such deals, implying the amounts are predictable based on typical industry structures. Q: Can you elaborate on the strategic agenda and how the Sobi partnership enables the TELAMAC-3 study?A: Jonathan Dickinson, CEO, reiterated that the Sobi partnership, announced earlier in the week, allows initiation of the TELAMAC-3 confirmatory phase 3 study in cutaneous T-cell lymphoma (CTCL). Innate will continue to run the study leveraging its expertise. At closing, Sobi pays $75 million upfront plus up to $40 million in near-term milestones tied to Sezary syndrome accelerated approval, with an additional $465 million in opt-in, regulatory, and commercial milestones plus double-digit royalties. For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Interested in Innate Pharma S.A. Sponsored ADR? Here are five stocks we like better. Lacutamab is Innate Pharma’s top near-term clinical focus, with FDA clearance for the confirmatory Phase 3 TELLOMAK-3 trial in cutaneous T-cell lymphoma. The company expects to start the study in the second half of 2026, subject to financing, and is pursuing non-dilutive funding options. IPH4502, Innate’s Nectin-4 ADC, is showing early antitumor activity in a Phase 1 dose-escalation study in advanced solid tumors, including patients previously treated with enfortumab vedotin. The company says it has reached the maximum tolerated dose and plans to share more data, including urothelial cancer results, in the second half of 2026. Monalizumab, partnered with AstraZeneca, remains a major value driver with Phase 3 PACIFIC-9 enrollment completed and data expected in the second half of 2026. Innate also highlighted continued progress on IPH5201, another AstraZeneca-partnered program, which showed encouraging interim response rates in resectable non-small cell lung cancer. Innate Pharma (NASDAQ:IPHA) said its first-quarter 2026 business update centered on three priority clinical assets: lacutamab in cutaneous T-cell lymphoma, the Nectin-4 antibody-drug conjugate IPH4502 in advanced solid tumors, and the AstraZeneca-partnered monalizumab program in non-small cell lung cancer. Chief Executive Officer Jonathan Dickinson said the company is continuing to execute “with discipline” and pointed to several expected catalysts in the second half of 2026, including the planned initiation of a confirmatory Phase 3 trial for lacutamab and a Phase 3 readout for monalizumab. He also said the company ended the quarter with a cash position of EUR 25.4 million as of March 31, 2026. → Rocket Lab Just Hit a New All-Time High—Time to Buy or Let It Breathe? Lacutamab, Innate’s anti-KIR3DL2 monoclonal antibody, is being developed for cutaneous T-cell lymphoma, including Sézary syndrome and mycosis fungoides. Dickinson said the company has received FDA clearance to proceed with TELLOMAK-3, a confirmatory Phase 3 trial, and expects to initiate the study in the second half of 2026, subject to financing. Chief Medical Officer Sonia Quaratino said prior Phase 2 TELLOMAK data showed “clinically meaningful and durable activity” in both mycosis fungoides and Sézary syndrome, along with quality-of-life improvement and a favorable safety and tolerability profile. Lacutamab has received FDA breakthrough therapy designation in relapsed or refractory Sézary syndrome, as well as FDA fast track designation, EMA PRIME designation and orphan drug status in the U.S. and Europe. → MercadoLibre Boldly Invests in Growth: Discount Deepens TELLOMAK-3 is planned as an open-label, multicenter, randomized comparative study in two cohorts of patients with cutaneous T-cell lymphoma who have failed at least one prior systemic therapy. In Sézary syndrome, patients who have failed at least one prior systemic therapy, including mogamulizumab, will be randomized to lacutamab or romidepsin. In mycosis fungoides, patients will be randomized to lacutamab or mogamulizumab. The primary endpoint in both cohorts is progression-free survival assessed by blinded independent central review. Stéphanie Cornen, vice president of investor relations, communication and commercial strategy, said Innate sees a focused commercial opportunity because most patients are treated in specialized academic centers. She cited estimates of about 300 incident Sézary syndrome patients per year and around 1,000 prevalent patients in the U.S., along with about 3,000 incident mycosis fungoides patients per year and prevalence of about 12,000 patients. → MP Materials Is Quietly Building a Rare Earth Powerhouse Cornen said Innate sees a stepwise commercial strategy, beginning with an initial opportunity of up to EUR 150 million in Sézary syndrome and expanding to more than EUR 500 million across Sézary syndrome and mycosis fungoides in the second-line setting. During the question-and-answer session, Dickinson said Innate is in advanced discussions regarding non-dilutive financing for lacutamab, including potential business development partnerships or royalty financing structures. Chief Operating Officer Yannis Morel said the company is confident it can execute an arrangement before the third quarter. Innate also highlighted progress with IPH4502, its Nectin-4 exatecan antibody-drug conjugate being evaluated in a Phase 1 study in advanced solid tumors. Dickinson said the study is approaching completion of enrollment in the dose-escalation phase and backfill cohorts, and the company continues to observe preliminary antitumor activity in heavily pretreated patients, including urothelial cancer patients previously treated with enfortumab vedotin, marketed as PADCEV. Morel described IPH4502 as designed to address limitations of first-generation Nectin-4 ADCs. He said the antibody binds to a distinct, non-overlapping epitope versus enfortumab on Nectin-4 and uses a stable, cleavable, hydrophilic linker with an exatecan payload. Morel said the payload is a topoisomerase I inhibitor with bystander activity and is not sensitive to resistance mechanisms related to MMAE, the payload used in enfortumab vedotin. Quaratino said the first-in-human study began in January 2025 at specialized cancer sites in the U.S. and France. She said the dose-escalation portion and cohort enrichment are nearing completion, the maximum tolerated dose has been reached and Innate has defined a “clear therapeutic window” with a favorable safety profile to date. Quaratino said the company sees a therapeutic gap in bladder cancer after progression on enfortumab vedotin plus pembrolizumab. She noted that, as of 2026, there is no single established gold standard for second-line treatment after that regimen, and said IPH4502 may be positioned to address that unmet need. In response to analyst questions, Quaratino said Innate expects to provide more detail on dose levels and potential go-forward indications at a clinical conference later this year. Dickinson said the data presentation is expected in the second half of the year and should include urothelial cancer data and next steps for the program. Innate also reviewed two programs partnered with AstraZeneca: monalizumab and IPH5201. Monalizumab, an anti-NKG2A monoclonal antibody, is being evaluated in PACIFIC-9, a Phase 3 randomized, double-blind study in unresectable stage 3 non-small cell lung cancer in patients who have not progressed after definitive concurrent chemoradiotherapy. Quaratino said enrollment has been completed and data are expected in the second half of 2026. Morel said the monalizumab agreement includes up to EUR 1.275 billion in milestones, of which Innate has received EUR 450 million and remains eligible for EUR 825 million. If approved, AstraZeneca would book sales, while Innate would receive double-digit royalties in the U.S. and the rest of the world. In Europe, Innate is contributing 30% of Phase 3 trial funding and would receive 50% of profit, with an option to co-promote. IPH5201, an anti-CD39 antibody, is being studied in the MATISSE Phase 2 trial in combination with durvalumab and neoadjuvant platinum-based chemotherapy in resectable non-small cell lung cancer. Quaratino said preplanned interim data presented at the AACR Annual Meeting showed a 35.7% pathological complete response rate in patients with PD-L1 expression above 1% and a 50% rate in patients with PD-L1 expression of at least 50%. She said the study is now focusing recruitment exclusively on patients with PD-L1-positive tumors, and no new or unexpected safety signals were identified. For IPH5201, Morel said the agreement is worth up to EUR 885 million in milestones, including EUR 60 million already received and EUR 825 million remaining. Innate has the option to co-fund a Phase 3 trial to receive 50% of European profit and co-promotion rights; otherwise, it would receive royalties in Europe, the U.S. and the rest of the world. Dickinson said Innate’s near-term priorities include initiating the TELLOMAK-3 Phase 3 study for lacutamab, presenting first-in-human IPH4502 data before the end of the year, and awaiting monalizumab’s PACIFIC-9 primary endpoint results in the second half of 2026. “Taken together, these three programs provide a clear set of value-driving catalysts across our portfolio,” Dickinson said. Innate Pharma SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body's innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments. The company's lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. The article "Innate Pharma Q1 Earnings Call Highlights" was originally published by MarketBeat. View MarketBeat's top stocks for May 2026.

Lacutamab TELLOMAK-3 confirmatory Phase 3 trial in cutaneous T-cell lymphoma (CTCL) remains planned for initiation in H2 2026, subject to non-dilutive financing options currently under negotiation, including pharma partnering and royalty structures IPH4502 (Nectin-4 ADC) continues to show preliminary anti-tumor activity with favorable safety profile to date; the maximum tolerated dose has been reached and enrollment in the Phase 1 dose escalation and cohort enrichment is nearing completion PACIFIC-9 Phase 3 trial, which includes monalizumab and is led by AstraZeneca, continues to advance toward a planned H2 2026 data readout IPH5201 (anti-CD39 antibody), developed in collaboration with AstraZeneca, showed encouraging early results presented in a Clinical Trials Plenary Session at AACR 2026, supporting continued investigation in the MATISSE Phase 2 study in non-small cell lung cancer (NSCLC) Cash position of €25.4 million1 as of March 31, 2026, with an anticipated cash runway until the end of Q3 2026 Conference call to be held today at 1:30 p.m. CEST / 7:30 a.m. EDT MARSEILLE, France, May 13, 2026--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today reported its business update and consolidated financial results for the quarter ending March 31, 2026. "We have continued to make solid progress across our priority clinical assets during the first quarter. We are approaching completion of enrollment in the Phase 1 dose escalation and backfill cohorts for IPH4502. In parallel, we have advanced the negotiations for non-dilutive financing options to allow initiation of the lacutamab confirmatory Phase 3 TELLOMAK-3 trial in CTCL. Finally, the Phase 3 PACIFIC-9 trial with AstraZeneca is planned for data readout in the second half of 2026. Separately, we were pleased to see encouraging results from the MATISSE Phase 2 trial presented at the AACR Annual Meeting 2026. It is exciting to see the continued advancement of our differentiated immunotherapy pipeline for patients with high unmet medical need," said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. Pipeline highlights: Lacutamab (anti-KIR3DL2 antibody): Cutaneous T-Cell Lymphoma The planned confirmatory Phase 3 TELLOMAK-3 trial is an open-label, multi-center, randomized, comparative study evaluating lacutamab in patients with Sézary syndrome and mycosis fungoides, who have failed at least one prior systemic therapy. TELLOMAK-3 includes two cohorts: a confirmatory cohort in Sézary syndrome, intended to support a potential accelerated approval based on existing TELLOMAK Phase 2 data, and a registrational cohort in mycosis fungoides, intended to support full approval. The primary endpoint of the study for both cohorts is progression-free survival (PFS) evaluated by blinded central review. Following the U.S. Food and Drug Administration (FDA) review of the Phase 3 protocol, with no further comments in November 2025, the trial is planned for initiation in H2 2026. The FDA provided encouraging feedback on the TELLOMAK Phase 2 results and the proposed regulatory pathway, which may support an accelerated approval in Sézary syndrome once the Phase 3 trial is underway. In February 2025, the FDA granted Breakthrough Therapy Designation to lacutamab for relapsed or refractory Sézary syndrome. The TELLOMAK Phase 2 trial is completed, and patients still on treatment at the end of the study continue to receive lacutamab through a Post Trial Access program. An abstract authored by ZS Associates entitled "Cutaneous T-Cell Lymphoma Epidemiology in the United States: A Real-World Data Analysis of Administrative Claims" has been accepted for publication in the official Abstract Book of the European Hematology Association Congress 2026. The analysis, sponsored by Innate, reports approximately 12,400 prevalent patients with mycosis fungoides (MF) and 1,100 with Sézary syndrome (SS), with ~2,900 and ~300 new cases per year, respectively. Peripheral T-Cell Lymphoma (PTCL) KILT (anti-KIR in T-Cell Lymphoma) Phase 2 trial, an investigator-sponsored, randomized study led by the Lymphoma Study Association (LYSA) evaluating lacutamab in combination with GEMOX (gemcitabine and oxaliplatin) versus GEMOX alone in patients with KIR3DL2-expressing relapsed/refractory PTCL, is ongoing. IPH4502 (Nectin-4 exatecan ADC): The IPH4502-101 Phase 1 study (NCT06781983), recruiting in France and in the United States, is evaluating the safety, tolerability, and preliminary anti-tumor activity of IPH4502 in advanced solid tumors known to express Nectin-4, including but not limited to urothelial carcinoma, non-small cell lung, breast, ovarian, gastric, esophageal, and colorectal cancers. The maximum tolerated dose has been reached and enrollment in the Phase 1 dose escalation and cohort enrichment is nearing completion. Preliminary anti-tumor activity continues to be observed in heavily pre-treated patients with advanced solid tumors, including in patients with urothelial cancer relapsed or refractory to enfortumab vedotin, with a favorable safety profile to date. Monalizumab (anti-NKG2A antibody), developed in collaboration with AstraZeneca: The PACIFIC-9 Phase 3 trial run by AstraZeneca evaluating durvalumab (anti-PD‑L1) in combination with monalizumab or AstraZeneca’s oleclumab (anti-CD73) in patients with unresectable, Stage III non-small cell lung cancer (NSCLC) who have not progressed following platinum-based chemoradiation therapy (CRT) is ongoing. Enrollment in the trial is complete, and data readout is expected in H2 2026. Other Clinical stage assets IPH5201 (anti-CD39 antibody, developed in collaboration with AstraZeneca): The MATISSE Phase 2 trial is evaluating IPH5201 in combination with durvalumab and platinum-based chemotherapy in the neoadjuvant lung cancer setting. Interim results from MATISSE Phase 2 were presented in a Clinical Trials Plenary Session at the AACR Annual Meeting 2026 on April 21, 2026 in San Diego, by Pr. Fabrice Barlesi (Institut Gustave Roussy). The pre-planned interim analysis was conducted on 40 patients with resectable early-stage (stage II–IIIA) NSCLC treated with perioperative IPH5201 in combination with durvalumab and platinum-based chemotherapy. The combination showed encouraging results with overall pathological complete response (pCR) rate of 27.5% (95% CI: 14.6–43.9). pCR rates were notably higher in patients with PD-L1-positive tumors, reaching 35.7% in PD-L1 ≥1% patients (n=28%) and 50.0% in PD‑L1 ≥50% patients (n=14). Higher baseline tumor CD39+ and CD8+ cell density was observed in patients achieving pCR/mPR, suggesting CD39 expression as a potentially emerging biomarker. The safety profile was comparable to that of preoperative platinum-based chemotherapy with durvalumab. Based on these encouraging results, the MATISSE study continues enrollment in the PD-L1 ≥1% patient population. IPH5301 (anti-CD73, proprietary): The investigator-sponsored CHANCES Phase 1 trial of IPH5301 with Institut Paoli-Calmettes is ongoing. IPH6101 (ANKET® anti-CD123, proprietary): Innate has initiated a research collaboration to further assess next steps of development. IPH6401/SAR’514 (ANKET® anti-BCMA, partnered with Sanofi): During the first quarter, Sanofi announced deprioritization of SAR’514, a trifunctional anti-BCMA NK-cell engager. Sanofi retains exclusive development and commercialization rights, and the license terms remain unchanged. Corporate Update: As previously announced, in line with its strategic focus, the Company has streamlined its organization. Planned layoffs were implemented through a redundancy plan which is completed. As of March 31, 2026, the balance available under our April 2023 sales agreement under the At-The-Market program remains at $75 million. Financial highlights for Q1 2026: Cash, cash equivalents and financial assets of the Company amounted to €25.4 million as of March 31, 2026. At the same date, financial liabilities amounted to €20.3 million. Revenue for the three-month period ending March 31, 2026, amounted to €2.6 million (€1.2 million for the same period in 2025). Revenue from collaboration and licensing agreements mainly resulted from the partial or entire recognition of the proceeds received pursuant to the agreements with AstraZeneca and Sanofi. About Innate Pharma: Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise on antibody-engineering and innovative target identification, Innate Pharma is developing innovative and differentiated next-generation antibody therapeutics. Innate Pharma is advancing a portfolio of differentiated potential first- and/or best-in-class assets, focused on areas of high unmet medical need, including IPH4502, a differentiated Nectin‑4 ADC developed in solid tumors, lacutamab, an anti-KIR3DL2 antibody developed in cutaneous T cell lymphomas and peripheral T cell lymphomas, and monalizumab, an anti-NKG2A antibody developed in collaboration with AstraZeneca in non-small cell lung cancer. Innate Pharma has established collaborations with leading biopharmaceutical companies, including Sanofi and AstraZeneca, as well as renowned academic and research institutions, to advance innovation in immuno-oncology. Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US. Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X. Information about Innate Pharma shares: Disclaimer on forward-looking information and risk factors: This press release contains certain forward-looking statements, including those within the meaning of applicable securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. All statements other than present and historical facts and conditions contained in this press release, including statements regarding the future results of operations and financial position, business strategy, plans and the Company’s objectives for future operations, are forward-looking statements. These are based on the management’s current beliefs, expectations and assumptions about future events, conditions and results and on information currently available to the management. When used in this press release, certain words, including "anticipate," "plan," "believe," "can," "could," "estimate," "project," "expect," "may," "might," "potential," "should," "will," or the negative of these and similar expressions, identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, enrolment, results and other milestones of its preclinical trials, the Company’s reliance on third parties to manufacture its product candidates, the Company’s commercialization efforts and the Company’s continued ability to raise capital to fund its development and product trials given its current cash position and the impact an inability to raise further financing would have on the Company’s ability to meet its financial or business objectives. For an additional discussion of risks and uncertainties, which could cause the Company's actual results, financial condition, performance or achievements to differ materially from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority ("AMF"), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission ("SEC"), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2025, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company’s website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame or at all. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country. View source version on businesswire.com: https://www.businesswire.com/news/home/20260512637251/en/ Contacts For additional information, please contact: Innate Pharma Stéphanie Cornen [email protected] Investor Relations [email protected] Media [email protected]

Encouraging early results catalyze continued investigation in the MATISSE Phase 2 study evaluating IPH5201, a first-in-class anti-CD39 monoclonal antibody, in combination with durvalumab and chemotherapy in resectable NSCLC; these results will be presented at the Clinical Trials Plenary Session at the AACR Annual Meeting 2026, on April 21 MARSEILLE, France, April 17, 2026--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), today announced that interim results from the MATISSE Phase 2 study evaluating IPH5201 in combination with durvalumab and platinum-based chemotherapy in resectable non-small cell lung cancer (NSCLC) will be presented in one of the Clinical Trials Plenary Sessions at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17–22, 2026 in San Diego, California. The MATISSE study (NCT05742607) is a single arm Phase 2 clinical trial evaluating perioperative IPH5201, an anti-CD39 blocking antibody, in combination with perioperative durvalumab (anti-PD-L1) in addition to neoadjuvant platinum-based chemotherapy in previously untreated patients with resectable NSCLC. The trial is designed to assess whether dual inhibition of the CD39 and PD-L1 pathways, together with chemotherapy, can enhance anti-tumor immune responses and improve clinical outcomes in early-stage lung cancer. These results follow a pre-planned interim analysis on 40 patients. The combination of IPH5201 with durvalumab and chemotherapy demonstrated higher pathological complete response (pCR) rates compared with the benchmark set by durvalumab plus chemotherapy alone. Notably, pCR was 35.7% and 50% in patients with tumors expressing PD-L1 ≥1% and PD-L1 ≥50%, respectively. Based on these results, the study continues to recruit patients with tumors expressing PD-L1≥1%. "Patients with resectable NSCLC remain at significant risk of recurrence, underscoring the need for novel perioperative treatment strategies. Disrupting the adenosine pathway through CD39 inhibition with IPH5201, in combination with PD-1 blockade and chemotherapy, could enhance anti-tumor immune responses—particularly in patients with PD-L1 positive tumors, where we observed up to 50% pCR rate in the MATISSE trial. This signal will be further investigated as we complete enrollment of the study in the PD-L1-positive population," commented Dr. Sonia Quaratino, Chief Medical Officer of Innate Pharma. The presentation will be available in the publication section of Innate Pharma’s website. Abstract details Dual CD39 and PD-L1 inhibition: Interim results from the Phase 2 MATISSE trial of IPH5201 plus durvalumab and platinum-based chemotherapy in patients with resectable NSCLC Abstract Code: CT231 Session: CTPL04 – Advances in Immunotherapy Session Date/Time: Tuesday, April 21, 2026, 10:45 – 11:00 AM PDT Presenter: Pr. Fabrice Barlesi, CEO of Institut Gustave Roussy About IPH5201 IPH5201 is a first-in-class monoclonal antibody targeting CD39, a key immunosuppressive enzyme in the adenosine pathway. CD39 is expressed on tumor-infiltrating immune and stromal cells and contributes to immunosuppression by degrading extracellular adenosine triphosphate (ATP) into adenosine monophosphate (AMP), which is then further degraded into adenosine by CD73. By blocking CD39, IPH5201 promotes the accumulation of immunostimulatory ATP and reduces the production of immunosuppressive adenosine, thereby enhancing anti-tumor immune responses. IPH5201 is being co-developed in collaboration with AstraZeneca and is currently being evaluated in the Phase 2 MATISSE trial (NCT05742607), a multicenter study investigating perioperative treatment with IPH5201 in combination with durvalumab (anti-PD-L1) and platinum-based chemotherapy in patients with resectable non-small cell lung cancer (NSCLC). The MATISSE trial is designed to assess anti-tumor activity, including pathological complete response, and safety, with the goal of determining whether dual inhibition of the CD39 and PD-L1 pathways, in combination with chemotherapy, can enhance anti-tumor immunity and improve clinical outcomes in early-stage NSCLC. About Innate Pharma Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise on antibody-engineering and innovative target identification, Innate Pharma is developing innovative and differentiated next-generation antibody therapeutics. Innate Pharma is advancing a portfolio of differentiated potential first- and/or best-in-class assets, focused on areas of high unmet medical need, including IPH4502, a differentiated Nectin-4 ADC developed in solid tumors, lacutamab, an anti-KIR3DL2 antibody developed in cutaneous T cell lymphomas and peripheral T cell lymphomas, and monalizumab, an anti-NKG2A antibody developed in collaboration with AstraZeneca in non-small cell lung cancer. Innate Pharma has established collaborations with leading biopharmaceutical companies, including Sanofi and AstraZeneca, as well as renowned academic and research institutions, to advance innovation in immuno-oncology. Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US. Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X. Information about Innate Pharma shares Disclaimer on forward-looking information and risk factors This press release contains certain forward-looking statements, including those within the meaning of applicable securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These are based on the management’s current beliefs, expectations and assumptions about future events, conditions and results and on information currently available to the management. When used in this press release, certain words, including "anticipate," "plan," "believe," "can," "could," "estimate," "project," "expect," "may," "might," "potential," "expect" "should," "will," or the negative of these and similar expressions, identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, enrolment, results and other milestones of its preclinical trials, the Company’s reliance on third parties to manufacture its product candidates, the Company’s commercialization efforts and the Company’s continued ability to raise capital to fund its development and product trials given its current cash position and the impact an inability to raise further financing would have on the Company’s ability to meet its financial or business objectives. For an additional discussion of risks and uncertainties, which could cause the Company's actual results, financial condition, performance or achievements to differ materially from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority ("AMF"), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission ("SEC"), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2025, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company’s website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame or at all. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country. View source version on businesswire.com: https://www.businesswire.com/news/home/20260417313341/en/ Contacts For more information Investors & Media Relations Innate Pharma Stéphanie Cornen [email protected] Investor Relations [email protected] Media [email protected]

This article first appeared on GuruFocus. Release Date: March 26, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Innate Pharma SA (NASDAQ:IPHA) has received FDA clearance to proceed with the Telemax 3 phase 3 trial for lacutamab in CTCL, with initiation expected in the second half of 2026. IPH 4,502 is showing early signs of anti-tumor activity in heavily pretreated patients, including those with urothelial cancer, and has a favorable safety profile. Monalizumab, in partnership with AstraZeneca, is progressing with the Pacific 9 phase 3 trial data readout expected in the second half of 2026. The company has streamlined its organization to support efficient decision-making and disciplined capital allocation. Innate Pharma SA (NASDAQ:IPHA) has a cash position of 44.8 million, providing funding visibility until the end of the third quarter of 2026. Operating expenses were 63 million, with a significant portion related to R&D, reflecting high costs associated with ongoing studies. Revenue and other income amounted to only 9 million, indicating limited income generation from current operations. The company is still in the process of evaluating financing options for the phase 3 study of lacutamab, indicating potential funding challenges. The collaboration revenue from the monalizumab program has dropped significantly, reflecting a shift in project management to AstraZeneca. There is a significant therapeutic gap in the post-EV setting for urothelial cancer, highlighting unmet needs that IPH 4,502 aims to address. Warning! GuruFocus has detected 7 Warning Signs with IPHA. Is IPHA fairly valued? Test your thesis with our free DCF calculator. Q: Can you provide additional specifics regarding the IPH 4,502 program and how it stands against competitors in the nectin 4 ADC space? A: Jonathan Dickinson, CEO: We are very excited about the IPH 4,502 program. The study is progressing well with significant interest. Recent competitive developments reinforce our positioning. As a Topo1 ADC, IPH 4,502 has a unique opportunity in the post-PAD setting, which was not available to MMAE-based ADCs. Sonia Quaratino, CMO: We have established the maximum tolerated dose and are encouraged by preliminary activity at therapeutic doses across different tumor types. Q: Regarding the Matisse interim data presentation at AACR, what should we expect from the program? A: Yannis Morell, COO: The Matisse trial, in collaboration with AstraZeneca, aims to generate sufficient data to validate the target and explore development in lung cancer. The interim analysis will cover the first 40 patients, with the trial continuing to include up to 70 patients. The data will be presented at AACR, focusing on efficacy. Q: With the collaboration revenue from the monalizumab program dropping, do you foresee any additional milestones, especially with the upcoming Pacific 9 readout? A: Frederic Lombard, CFO: The revenue drop relates to the old agreement. The project is now entirely in AstraZeneca's hands, with accounting treatment differing. Future development will depend on upcoming results expected in the second half of the year. Q: Can you provide updates on partnership discussions for Lacutamab and potential deal structures? A: Jonathan Dickinson, CEO: Our priority is to get Lacutamab to market quickly. Timelines for approval look similar for both BD options and royalty financing. We will run the phase 3 studies, controlling timelines and regulatory interactions. Our decision will focus on long-term shareholder value, evaluating both BD partnerships and royalty financing structures. Q: What can we expect from the upcoming data readouts for the ADC, and what sales infrastructure are you planning for Lacutamab? A: Sonia Quaratino, CMO: We aim to present a comprehensive safety profile, PK data, and efficacy readouts, including nectin 4 expression in tumors. Jonathan Dickinson, CEO: For sales infrastructure, if we proceed independently, a small team will suffice due to the concentrated treatment landscape in the US, requiring around 20 salespeople, 5-6 medical affairs staff, and a few access personnel. For the complete transcript of the earnings call, please refer to the full earnings call transcript.